Status:

COMPLETED

Vitamin D Supplementation in Diabetic Nephropathy

Lead Sponsor:

University of Alberta

Conditions:

Sub-optimal Vitamin D Status

Bone Disease

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

Diabetes is a life-long disease that is getting more common in Canada. One of the most common problems in people with kidney disease is diabetes and low bone mineral density (BMD). This can lead to a ...

Detailed Description

Abstract: Vitamin D has a well-established role in bone health and the prevention of fractures which are associated with increased morbidity and mortality, and reduced quality of life. However, many ...

Eligibility Criteria

Inclusion

  • Clinical diagnoses of diabetes (type 1 or 2) and stage 2-4 chronic kidney disease (glomerular filtration rate: 15-89 ml/min/1.73m2)

Exclusion

  • Patients with co-morbid conditions known to affect vitamin D metabolism including gastrointestinal, liver, rheumatoid or bone disorders (e.g. hyperthyroidism, untreated celiac disease, cancer, Paget's disease, sarcoidosis, malabsorption, etc). Individuals with severe, permanent vision impairment will be excluded as this will preclude them from reading supplement labels accurately and safely. Pregnant women will be excluded as DXA scans are not recommended during pregnancy. Patients weighing \>136kg will be excluded as the DXA table cannot accommodate this weight.
  • Patients on drug therapy known to interfere with vitamin D (e.g. oral glucocorticoids, cholestyramine, colestipol, mineral oil, Orlistat, digoxin, antacids).
  • Patients with stage 5 CKD (GFR \<15ml/min/1.73m2), receiving dialysis or on kidney transplant list.
  • Patients with pre-existing hypercalcemia (\>2.75mmol/l), hyperphosphatemia (\>2.0mmol/l), severe hyperparathyroidism (PTH \>600pg/ml), and serum 25(OH)D \>200nmol/l.
  • Patients with serum 25(OH)D \<37.5nmol/l at time of study entry/screening to control for correction of vitamin D deficiency.

Key Trial Info

Start Date :

October 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2015

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT01476501

Start Date

October 1 2011

End Date

December 1 2015

Last Update

August 31 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinical Research Unit, University of Alberta

Edmonton, Alberta, Canada, T6G 0K2